With 37.34% Distance From Low, Is Macrogenics Inc (NASDAQ:MGNX) Poised For More Gains?

In last trading session, Macrogenics Inc (NASDAQ:MGNX) saw 0.4 million shares changing hands with its beta currently measuring 1.69. Company’s recent per share price level of $1.58 trading at $0.04 or 2.60% at ring of the bell on the day assigns it a market valuation of $99.68M. That closing price of MGNX’s stock is at a discount of -265.19% from its 52-week high price of $5.77 and is indicating a premium of 37.34% from its 52-week low price of $0.99. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.42 million shares which gives us an average trading volume of 720.28K if we extend that period to 3-months.

For Macrogenics Inc (MGNX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.57. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.75 in the current quarter.

Macrogenics Inc (NASDAQ:MGNX) trade information

Upright in the green during last session for gaining 2.60%, in the last five days MGNX remained trading in the green while hitting it’s week-highest on Wednesday, 05/14/25 when the stock touched $1.58 price level, adding 3.36% to its value on the day. Macrogenics Inc’s shares saw a change of -51.38% in year-to-date performance and have moved 10.49% in past 5-day. Macrogenics Inc (NASDAQ:MGNX) showed a performance of 33.90% in past 30-days. Number of shares sold short was 5.68 million shares which calculate 6.16 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 2.5 to the stock, which implies a rise of 36.8% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 3. It follows that stock’s current price would drop -26.58% in reaching the projected high whereas dropping to the targeted low would mean a loss of -26.58% for stock’s current value.

Macrogenics Inc (MGNX) estimates and forecasts

This year revenue growth is estimated to fall -57.86% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 11.01M for the same. And 6 analysts are in estimates of company making revenue of 21.05M in the next quarter. Company posted 10.8M and 110.71M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 19.47% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -113.89% while estimates for its earnings growth in next 5 years are of -23.25%.

Macrogenics Inc (NASDAQ:MGNX)’s Major holders

Insiders are in possession of 2.92% of company’s total shares while institution are holding 87.70 percent of that, with stock having share float percentage of 90.34%. Investors also watch the number of corporate investors in a company very closely, which is 87.70% institutions for Macrogenics Inc that are currently holding shares of the company. BELLEVUE GROUP AG is the top institutional holder at MGNX for having 9.94 million shares of worth $42.25 million. And as of 2024-06-30, it was holding 15.8662 of the company’s outstanding shares.

The second largest institutional holder is ARMISTICE CAPITAL, LLC, which was holding about 6.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.5749 of outstanding shares, having a total worth of $25.5 million.

On the other hand, WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 2.82 shares of worth $4.46 million or 4.47% of the total outstanding shares. The later fund manager was in possession of 1.97 shares on Dec 31, 2024 , making its stake of worth around $3.12 million in the company or a holder of 3.13% of company’s stock.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.